Your post is a welcome rebuttal to the misleading Seeking Alpha hatchet job that questions CYCC use of money to continue SEAMLESS. The Alpha article completely ignores that the majority of trial expenses have already been incurred and it would be against shareholder interests to prematurely terminate a trial that probably has a 50/50 chance of getting approval in rest of world, if not the U.S.
Australia and Europe have much easier approval standards for medical devices. ETRM does not have the resources to do full launches in those regions without a well-funded partner(FDA approval will hopefully cure those problems.)
(I agree and bought 7000 shares below .70; time and again I have seen an outlier in a company's pipeline produce a positive surprise or modest partnership, that jump started a severely depressed stock price. It is laughable to me to hear critics of the CEO acting as if they themselves are as pure as the driven snow! )
Three product candidates are currently in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analogue, is in Phase 3 development for the treatment of acute myeloid leukemia (AML) in the elderly under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration and Phase 2 studies for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel Pharmaceuticals' strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.
invest_a_mint: Your description of the CEO is boilerplate and has been similarly expressed for hundreds of CEOS on Yahoo. Surprisingly, company stock prices some of the most hated CEOs on Yahoo eventually outperform the market.
Many small biotech and medical device companies get heavily discounted in late December only to bounce back in January. The Russian ruble crisis and freefalling oil prices are creating extra turmoil in the market. In times like this little price support is given to companies like ETRM; this enable new entrants to steal shares at ridiculously low prices.
I owned CYCC a couple years ago and jumped back in for 7000 shares at about .695 and listened to the webcast. The relatively small share float and the fact that other indications in CYCC's pipeline could generate positive press releases going into 2015, makes a speculative price bump fairly likely. The company's decent cash position is a plus.
Dr Robinson has all her expenses paid by the conference and may well get a funding commitment while there. A recently established Dubai based medical research fund has $700 million to spend.
Folks, I guarantee you won't as retail traders be able to buy GOVX at the ultra lows posted today. These are manipulated trades in collusion to create a panic mentality. Remember this is OTC!
Black box trading algorithms factor in the actions of nervous Nellies like you and throw out volume spikes to harvest cheap shares. GOVX has dozens of applications out to foundations and government entities for grants
Inns: I also get this FREE newsletter which said "SetPoint Medical is starting a clinical trial to treat Crohn's disease patients with its implantable neuromodulation device. The startup previously reported a positive pilot study of the device to treat rheumatoid arthritis. Stimulation of the vagus nerve is expected to activate the body's natural reflexes to produce a systemic anti-inflammatory effect, thereby improving the symptoms of inflammatory disease.
"AdvaMed's Medical Technology Learning Institute (MTLI) will be conducting workshops on the specific provisions of the new law next month in Washington D.C. (Dec. 8-9) and San Francisco (Dec. 11-12), to help manufacturers adapt to the new requirements.
"The workshops will provide an early opportunity for companies to hear directly from Japan regulatory officials about the details of the new requirements.
The world's second largest drug market just became easier and faster for VBLOC to enter:
WASHINGTON, D.C. – Stephen J. Ubl, president and CEO of the Advanced Medical Technology Association (AdvaMed), today released the following statement in conjunction with the Nov. 25 implementation date for Japan's new Pharmaceutical and Medical Device Law (PMDL):
"AdvaMed applauds the entry into force of Japan's medical technology law, which regulates medical devices separately from drugs for the first time. Approved by the Japanese government one year ago, the PMDL creates a framework for regulation of medical devices and diagnostics that takes into account their unique characteristics and will help improve patient access to safe and effective medical innovations in Japan – the world's second largest market for medical technology products.
This very significant development will have a major, positive impact on medical technology manufacturers by streamlining regulatory requirements. For example, the new law expands the scope of products eligible for third-party certification, allows quality inspections to be conducted for product groupings as opposed to individual products, and simplifies the manufacturer accreditation process.
"The device-specific regulatory framework will dovetail with Japan's regulatory agency performance plan to facilitate timely product approvals in the country. Implemented in April, the updated performance plan has the ambitious goal of making Japan faster than the U.S. FDA in approving the most advanced category of medical devices.
If you look at the historical volume record, right here on Yahoo, you will see that OTC stocks tend to trade very thinly except for news events like the Ebola scare. Any positive news like additional grants or partnerships will double or triple GOVX with high volume. All I can advise is buy the dips. Zacks usually shyes away from OTC stocks, but they are very bullish on GOVX.
notamusedaa: do you still think the world is flat? Everything you said is completely wrong. Virtually 100% of companies issue a PR within 24 hours of an FDA decision-there is NOT a lot of work; the PRs have already been prepared in several formats.
Pharm: It was the sponsor who made the "hoping to have a decision for today's event" comment, NOT the company.
Ade: VBLOC does NOT have a monopoly on anything! In Thursday's presentation it was mentioned that there are a number of companies competing with ETRM for future approvals. The MONOPOLY is with the stingy payers.